Literature DB >> 11195127

Treatment of stages 2 and 3 giant-cell tumor.

K Labs1, C Perka, R G Schmidt.   

Abstract

During the period from August 1986 to August 1992, we treated 23 patients with giant cell tumors stage 2 or 3, according to the classification by Campanacci et al.. We analyzed the therapeutic options, complications, local recurrence rate, and functional results after a mean follow-up of 56 months (range 31-89 months). Intralesional resections were performed in 15 and wide resections in 8 patients. The majority of intralesional resections were performed for stage 2 tumors and the majority of en-bloc resections for stage 3 tumors. The overall local recurrence rate was 8.7%, but we observed local recurrence only in intralesional resections. Our experiences suggest that a subtle surgical technique with respect to oncological requirements is the most important element in the avoidance of local recurrence. Stage 2 tumors associated with weight-bearing anatomical structures should be treated with intralesional curettage and bone cement. Stage 3 tumors are limited as to their surgical options and are determined in some cases by their localization and the degree of bone destruction. Wide resections should be reserved mainly for stage 3 tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11195127     DOI: 10.1007/s004020000158

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  13 in total

1.  Which treatment is the best for giant cell tumors of the distal radius? A meta-analysis.

Authors:  Yu-Peng Liu; Kang-Hua Li; Bu-Hua Sun
Journal:  Clin Orthop Relat Res       Date:  2012-07-07       Impact factor: 4.176

2.  Comparison of the degenerative changes in weight-bearing joints following cementing or grafting techniques in giant cell tumour patients: medium-term results.

Authors:  K Szalay; I Antal; J Kiss; M Szendroi
Journal:  Int Orthop       Date:  2006-09-13       Impact factor: 3.075

3.  In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage.

Authors:  Liang Chen; Xiao-Yi Ding; Chengs-Sheng Wang; Ming-Jue Si; Lian-Jun Du; Wei-Bin Zhang; Yong Lu
Journal:  Radiol Med       Date:  2014-03-07       Impact factor: 3.469

Review 4.  Giant cell tumour of bone: a new evaluating system is necessary.

Authors:  Han Wang; Ningjun Wan; Yongcheng Hu
Journal:  Int Orthop       Date:  2012-10-05       Impact factor: 3.075

5.  Giant cell tumor of bone: risk factors for recurrence.

Authors:  Frank M Klenke; Doris E Wenger; Carrie Y Inwards; Peter S Rose; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2010-08-13       Impact factor: 4.176

6.  Salvaging the Unsalvageable Giant Cell Tumors of Bone: The 'Longitudinal Sandwich Technique'.

Authors:  Rishi Ram Poudel; Akshay Tiwari; Aakriti Jain; Vivek Verma
Journal:  Indian J Surg Oncol       Date:  2022-05-06

7.  Conservative treatment of Campanacci grade III proximal humerus giant cell tumors.

Authors:  Richard D Lackman; Eileen A Crawford; Joseph J King; Christian M Ogilvie
Journal:  Clin Orthop Relat Res       Date:  2008-11-06       Impact factor: 4.176

8.  Custom prosthetic replacement for distal radial tumours.

Authors:  Mayil Vahanan Natarajan; Jagadesh Chandra Bose; J Viswanath; Navin Balasubramanian; Mohamed Sameer
Journal:  Int Orthop       Date:  2009-02-26       Impact factor: 3.075

9.  Local recurrences after curettage and cementing in long bone giant cell tumor.

Authors:  Kabul C Saikia; Tulsi D Bhattacharyya; Sanjeev K Bhuyan; Bikas Bordoloi; Bharat Durgia; Firoz Ahmed
Journal:  Indian J Orthop       Date:  2011-03       Impact factor: 1.251

10.  Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Authors:  Piotr Rutkowski; Stefano Ferrari; Robert J Grimer; Paul D Stalley; Sander P D Dijkstra; Andrzej Pienkowski; Gualter Vaz; Jay S Wunder; Leanne L Seeger; Amy Feng; Zachary J Roberts; Bruce A Bach
Journal:  Ann Surg Oncol       Date:  2015-06-02       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.